• Je něco špatně v tomto záznamu ?

Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting

T. Etrych, P. Chytil, T. Mrkvan, M. Šírová, B. Říhová, K. Ulbrich

. 2008 ; 132 (3) : 184-192.

Jazyk angličtina Země Nizozemsko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11017380
E-zdroje

NLK ScienceDirect (archiv) od 1993-01-01 do 2009-12-31

Synthesis, physicochemical behavior, tumor accumulation and preliminary anticancer activity of a new biodegradable graft copolymer-doxorubicin (DOX) conjugates designed for passive tumor targeting were investigated. In the graft high-molecular-weight conjugates the multivalent N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer was grafted with a similar but semitelechelic HPMA copolymer; both types of polymer chains were bearing doxorubicin attached by hydrazone bonds enabling intracellular pH-controlled drug release. The polymer grafts were attached to the main chain through spacers, degradable enzymatically or reductively, facilitating, after the drug release, intracellular degradation of the graft polymer carrier to short fragments excretable from the organism by glomerular filtration. The graft polymer-DOX conjugate exhibited prolonged blood circulation and enhanced tumor accumulation in tumor-bearing mice indicating the important role of the EPR effect in the anticancer activity. The graft polymer-DOX conjugates showed a significantly higher antitumor activity in vivo than DOX.HCl or the linear polymer conjugate when tested in mice bearing 38C13 B-cell or EL4 T-cell lymphoma, with a significant number of long-term-surviving (LTS) mice with EL4 T-cell lymphoma treated with a single dose 15 mg DOX equiv./kg on day 10.

000      
03698naa 2200625 a 4500
001      
bmc11017380
003      
CZ-PrNML
005      
20121129101057.0
008      
110629s2008 ne e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Etrych, Tomáš $7 xx0068504
245    10
$a Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting / $c T. Etrych, P. Chytil, T. Mrkvan, M. Šírová, B. Říhová, K. Ulbrich
314    __
$a Institute of Macromolecular Chemistry AS CR, v.v.i., Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic.
520    9_
$a Synthesis, physicochemical behavior, tumor accumulation and preliminary anticancer activity of a new biodegradable graft copolymer-doxorubicin (DOX) conjugates designed for passive tumor targeting were investigated. In the graft high-molecular-weight conjugates the multivalent N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer was grafted with a similar but semitelechelic HPMA copolymer; both types of polymer chains were bearing doxorubicin attached by hydrazone bonds enabling intracellular pH-controlled drug release. The polymer grafts were attached to the main chain through spacers, degradable enzymatically or reductively, facilitating, after the drug release, intracellular degradation of the graft polymer carrier to short fragments excretable from the organism by glomerular filtration. The graft polymer-DOX conjugate exhibited prolonged blood circulation and enhanced tumor accumulation in tumor-bearing mice indicating the important role of the EPR effect in the anticancer activity. The graft polymer-DOX conjugates showed a significantly higher antitumor activity in vivo than DOX.HCl or the linear polymer conjugate when tested in mice bearing 38C13 B-cell or EL4 T-cell lymphoma, with a significant number of long-term-surviving (LTS) mice with EL4 T-cell lymphoma treated with a single dose 15 mg DOX equiv./kg on day 10.
590    __
$a bohemika - dle Pubmed
650    _2
$a akrylamidy $x aplikace a dávkování $x farmakokinetika $x farmakologie $x chemická syntéza $7 D000178
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorová antibiotika $x aplikace a dávkování $x farmakokinetika $x farmakologie $x chemická syntéza $7 D000903
650    _2
$a biologický transport $7 D001692
650    _2
$a buněčné linie $7 D002460
650    _2
$a farmaceutická chemie $7 D002626
650    _2
$a léky s prodlouženým účinkem $7 D003692
650    _2
$a doxorubicin $x aplikace a dávkování $x farmakokinetika $x farmakologie $x chemická syntéza $7 D004317
650    _2
$a nosiče léků $7 D004337
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a hydrolýza $7 D006868
650    _2
$a injekce intravenózní $7 D007275
650    _2
$a lymfom $x farmakoterapie $x metabolismus $x patologie $7 D008223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C3H $7 D008809
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a molekulová hmotnost $7 D008970
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a práce podpořená grantem $7 D013485
700    1#
$a Chytil, Petr. $7 _AN032430
700    1_
$a Mrkvan, Tomáš $7 xx0062385
700    1_
$a Šírová, Milada $7 xx0127158
700    1_
$a Říhová, Blanka, $d 1942- $7 jo20000073671
700    1_
$a Ulbrich, Karel, $d 1947- $7 jo2004259877
773    0_
$t Journal of Controlled Release $w MED00002621 $g Roč. 132, č. 3 (2008), s. 184-192
910    __
$a ABA008 $b x $y 2
990    __
$a 20110720113703 $b ABA008
991    __
$a 20121129101125 $b ABA008
999    __
$a ok $b bmc $g 864254 $s 727193
BAS    __
$a 3
BMC    __
$a 2008 $x MED00002621 $b 132 $c 3 $d 184-192 $m Journal of controlled release $n J Controlled Release
LZP    __
$a 2011-3B09/BBjvme

Najít záznam